Innovent Biologics is planning a second filing for its dual GLP-1/glucagon agonist mazdutide in China, as it tries to carve out a share of a market currently dominated by Novo Nordisk and E
Pfizer is advancing on a broad front in its attempt to catch up with Novo Nordisk and Eli Lilly in the obesity drug category – but has now decided on a lead candidate.
There’s no data from a head-to-head trial directly comparing Eli Lilly and Novo Nordisk’s GLP-1 agonist drugs yet, but an observational study has found that Lilly’s tirzepatide seems to be
Eli Lilly has bolstered its inflammatory bowel disease (IBD) pipeline with a $3.2 billion bid to acquire Morphic and its mid-stage oral integrin therapy MORF-057.
Eli Lilly finally has FDA approval for its amyloid-busting Alzheimer’s disease therapy donanemab and will launch it at a cost it claims could deliver savings compared to a rival therapy fro
Eli Lilly has lined up another deal in the radiopharmaceutical sector, paying $140 million to partner drugs developed by Radionetics Oncology and taking an option on buying the company outr
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh